Rebecca Brown, MD

National Institutes of Health
Bethesda, United States

Disclosure information not submitted.

Presentation(s):

• SAT-560 - Dangerous Lows after Extreme Highs: Hypoglycemia Unawareness in Type B Insulin Resistance

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-583 - High Predicted Cardiovascular Event Risk in Patients with Lipodystrophy Versus Pathogenic Insulin Receptor Variants

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-632 - Use of SGLT2 Inhibitors in Type A Insulin Resistance

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-653 - Cardiovascular Burden in Lipodystrophy Syndromes: Findings from the LD-Lync Study

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• ORF07-03 - Cardiovascular Burden in Lipodystrophy Syndromes: Findings from the LD-Lync Study

  Saturday, June 13, 2026
  9:55 AM - 10:00 AM CT

• ORF33-05 - Effects of Insulin Resistance in Different Insulin Signaling Pathways on Vascular Function : Lipodystrophy Compared to Pathogenic Variants of the Insulin Receptor

  Sunday, June 14, 2026
  2:15 PM - 2:30 PM CT

• MON-676 - Cancer Burden Across Lipodystrophy Subtypes: Results from the LD-Lync Study

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-688 - Metreleptin Reduces Circulating Branched-Chain Amino Acids Independent of Dietary Intake in Lipodystrophy

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• ORF44-01 - Metreleptin Reduces Circulating Branched-Chain Amino Acids Independent of Dietary Intake in Lipodystrophy

  Monday, June 15, 2026
  9:30 AM - 9:35 AM CT